Advanced Medical Optics, Inc.(AMO) (NYSE: EYE), a global ophthalmic surgical and eye care productscompany, announced today from the XXIV Congress of the European Society ofCataract and Refractive Surgeons (ESCRS) the launch of the TECNIS(R) CLintraocular lens (IOL). The TECNIS(R) CL IOL is the latest advance to theTECNIS(R) silicone IOL.

The TECNIS(R) CL IOL can be implanted with the UNFOLDER(TM) SilverSeries Implantation Systems and the Silver Advanced Cartridge through a2.8mm incision. It permanently replaces both the Z9000 and Z9001 TECNIS(R)silicone IOL models.

"The TECNIS(R) CL IOL provides the same FDA-approved claims andexcellent outcomes as the original TECNIS(R) lens but with a moreuser-friendly design," said AMO Corporate Vice President and ChiefMarketing Officer Russ Trenary. "We expect the TECNIS(R) CL lens to speedsurgeon migration from older-generation silicone lenses to the superiorTECNIS(R) optical design. The launch of the TECNIS(R) CL lens is anexcellent example of how we're continuing to refine our IOL offeringsthrough disciplined product lifecycle management."

The U.S. Centers for Medicare and Medicaid Services (CMS) extended NewTechnology Intraocular Lens (NTIOL) status to the TECNIS(R) CL lens inAugust. The TECNIS(R) and TECNIS(R) CL lenses are the first and onlyFDA-approved IOLs with claims for reduced spherical aberration, improvedfunctional vision and improved night driving simulator performance.

NTIOL designation provides for additional Medicare reimbursement of $50per lens for ambulatory surgical centers, which perform more than half ofall cataract surgeries in the United States. An NTIOL is defined as an IOLthat CMS determines has been approved by the FDA with labeling andadvertising claims of specific clinical advantages and superiority overexisting IOLs with regard to reduced risk of intraoperative orpost-operative complication or trauma, accelerated postoperative recovery,reduced induced astigmatism, improved postoperative visual acuity, morestable postoperative vision, or other comparable clinical advantages.

The TECNIS(R) CL IOL is available now in Europe and AMO plans to beginshipping the lens next month in the United States, Canada and Asia Pacific,and to Japan by mid-2007. For more information, visit: http://www.TECNISIOL.com .

AMO is a global medical device leader focused on the discovery anddelivery of innovative vision technologies that optimize the quality oflife for people of all ages. Products in the cataract/implant line includeintraocular lenses, phacoemulsification systems, viscoelastics, and relatedproducts used in cataract and refractive lenticular surgery. Products inthe laser vision correction line include laser systems, wavefrontdiagnostic systems, microkeratomes and related products used in cornealrefractive surgery. AMO owns or has the rights to such ophthalmic surgicalproduct brands as ReZoom(TM), Clariflex(R), Sensar(R), CeeOn(R), Tecnis(R)and Verisyse(TM) intraocular lenses, STAR S4 IR(TM) laser vision correctionsystem, WaveScan Wavefront(R) System, CustomVue(TM) procedure, Sovereign(R)and Sovereign(R) Compact(TM) phacoemulsification systems with WhiteStar(R)technology, Amadeus(TM) and Amadeus(TM) II microkeratomes, Healon(R)viscoelastics, and the Baerveldt(R) glaucoma shunt. Products in the contactlens care line include disinfecting solutions, enzymatic cleaners and lensrewetting drops. Among the eye care product brands the company possessesare COMPLETE(R) Moisture PLUS(TM), COMPLETE(R) Blink-N-Clean(R),Consept(R)F, Consept(R) 1 Step, Oxysept(R) 1 Step, UltraCare(R),Ultrazyme(R), Total Care(TM) and blink(TM) branded products. Amadeus is alicensed product of, and a trademark of, SIS, Ltd. AMO is based in SantaAna, California, and employs approximately 3,600 worldwide. The company hasoperations in 24 countries and markets products in approximately 60countries. For more information, visit the company's Web site athttp://www.amo-inc.com/ .

This press release contains forward-looking statements about AMO,including Mr. Trenary's statements and those relating to the launch andfeatures of the product. All forward-looking statements in this pressrelease are based on estimates and assumptions and represent AMO's judgmentonly as of the date of this press release. Actual results may differ fromcurrent expectations based on a number of factors including but not limitedto market developments, expanded clinical experience, unexpected delays inmanufacturing, and unexpected regulatory or quality issues. Therefore, thereader is cautioned not to rely on these forward-looking statements. AMOdisclaims any intent or obligation to update these forward-lookingstatements.

This is cache, read story here